Exeliom Biosciences

Exeliom Biosciences is a clinical-stage biotech pioneering innate immune conditioning through its lead live biotherapeutic, EXL01. Originating from the discovery of *Faecalibacterium prausnitzii*'s role in gut immunity, EXL01 targets the NOD2-CARD9 pathway to reprogram macrophages and overcome resistance to cancer immunotherapies. The company has advanced EXL01 into multiple Phase 2 trials in oncology and Crohn's disease, supported by a proprietary, scalable manufacturing platform for anaerobic bacteria. With a lean team and backing from European and U.S. grants, Exeliom is positioning EXL01 as a potential backbone therapy in immuno-oncology and IBD.

Proprietary platform for developing and manufacturing live biotherapeutic products (LBPs) based on immunomodulatory commensal bacteria, specifically targeting the NOD2-CARD9 innate immune pathway. Includes a scalable GMP manufacturing process for anaerobic fermentation.

In immuno-oncology, Exeliom competes with other ICI combination approaches (e.g., T-cell engagers, cytokine therapies, other microbiome modulators) but is differentiated by its specific targeting of the NOD2-CARD9 macrophage pathway. In the live biotherapeutic space, its scalable anaerobic manufacturing provides a key operational advantage over many peers.